This is a market share move thats why MD would partner up now.
When the EU License Acquisition is complete, RedHawk Pharma will own approximately 120 generic EU licensing assets and have approximately $15,000,000 of tax loss carryforwards available to offset future profits in the United Kingdom. The Company said it believes this new alliance with IPG will better position RedHawk Pharma to successfully integrate EcoGen and the EU License Acquisition, manage the anticipated growth of this business unit, and enhance the probability of successfully completing other organic and strategic business opportunities in the future.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.